Neurotrophic factor production accelerator
The present invention relates to an a neurotrophic factor production accelerator comprising, as an active ingredient, a compound represented by the formula (I) below: wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, and the above groups may be substituted with halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, and the above groups may be substituted with halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, Y is —CO—, —SO 2 — or —CONH—, a salt, a prodrug or a solvate thereof. According to the present invention, a neurotrophic factor production accelerator, which is useful for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, can be provided.
1 . A neurotrophic factor production accelerator comprising, as an active ingredient, a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.
2 . The accelerator of claim 1 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate.
3 . A method for accelerating neurotrophic factor production, which comprises administering, to a mammal, a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.
4 . The method of claim 3 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate.
5 - 6 . (canceled)
7 . A pharmaceutical composition for accelerating neurotrophic factor production, which comprises a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
8 . The pharmaceutical composition of claim 7 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate.
9 . A commercial package comprising the pharmaceutical composition of claim 7 , and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for accelerating neurotrophic factor production.
10 . An agent for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, which comprises, as an active ingredient, a compound having a neurotrophic factor production accelerating activity.
11 . The agent of claim 10 , wherein the motor nervous system or peripheral nervous system disease is selected from the group consisting of a peripheral nerve disorder (neuropathy, diabetic nervous disease), myelopathy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Guillain-Barre' syndrome, Huntington's chorea and neuropathic pain.
12 . The agent of claim 10 , wherein the compound having a neurotrophic factor production accelerating activity is a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.
13 . The agent of claim 12 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperaznyl)-p-fluorobenzamide monohydrate.
14 . A method of preventing or treating a motor nervous system or peripheral nervous system disease, which comprises administering a compound having a neurotrophic factor production accelerating activity to a mammal.
15 . The method of claim 14 , wherein the motor nervous system or peripheral nervous system disease is selected from the group consisting of a peripheral nerve disorder (neuropathy, diabetic nervous disease), myelopathy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Guillain-Barre' syndrome, Huntington's chorea and neuropathic pain.
16 . The method of claim 14 , wherein the compound having a neurotrophic factor production accelerating activity is a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.
17 . The method of claim 16 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate.
18 - 21 . (canceled)
22 . A pharmaceutical composition for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease, which comprises a compound having a neurotrophic factor production accelerating activity and a pharmaceutically acceptable carrier.
23 . The pharmaceutical composition of claim 22 , wherein the motor nervous system or peripheral nervous system disease is selected from the group consisting of a peripheral nerve disorder (neuropathy, diabetic nervous disease), myelopathy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Guillain-Barre' syndrome, Huntington's chorea and neuropathic pain.
24 . The pharmaceutical composition of claim 22 , wherein the compound having a neurotrophic factor production accelerating activity is a compound represented by the following formula (I):
wherein R 1 is lower alkyl, aryl, ar(lower)alkoxy, or a heterocyclic group, the above groups being optionally substituted by halogen, R 2 is a hydrogen atom or lower alkyl, R 3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO 2 — or lower alkylene, X is N or CH, and Y is —CO—, —SO 2 — or —CONH—, a salt thereof, a prodrug thereof or a solvate thereof.
25 . The pharmaceutical composition of claim 24 , wherein the compound represented by the formula (I) is N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate.
26 . A commercial package comprising the pharmaceutical composition of claim 22 , and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of a motor nervous system or peripheral nervous system disease.